The Accessibility in the External Part of the TM5 of the Glutamate Transporter EAAT1 Is Conformationally Sensitive during the Transport Cycle

Xiuping Zhang¹, Shaogang Qu²*

¹ China-America Cancer Research Institute, Guangdong Medical College, Dongguan, Guangdong, China, ² Department of Immunology, Southern Medical University, Guangzhou, Guangdong, China

Abstract

Background: Excitatory amino acid transporter 1 (EAAT1) is a glutamate transporter which is a key element in the termination of the synaptic actions of glutamate. It serves to keep the extracellular glutamate concentration below neurotoxic level. However, the functional significance and the change of accessibility of residues in transmembrane domain (TM) 5 of the EAAT1 are not clear yet.

Methodology/Principal Findings: We used cysteine mutagenesis with treatments with membrane-impermeable sulfhydryl reagent MTSET [(2-trimethylammonium) methanethiosulfonate] to investigate the change of accessibility of TM5. Cysteine mutants were introduced from position 291 to 300 of the cysteine-less version of EAAT1. We checked the activity and kinetic parameters of the mutants before and after treatments with MTSET, furthermore we analyzed the effect of the substrate and blocker on the inhibition of the cysteine mutants by MTSET. Inhibition of transport by MTSET was observed in the mutants L296C, I297C and G299C, while the activity of K300C got higher after exposure to MTSET. Vmax of L296C and G299C got lower while that of K300C got higher after treated by MTSET. The L296C, G299C, K300C single cysteine mutants showed a conformationally sensitive reactivity pattern. The sensitivity of L296C to MTSET was potentiated by glutamate and TBOA, but the sensitivity of G299C to MTSET was potentiated only by TBOA.

Conclusions/Significance: All these facts suggest that the accessibility of some positions of the external part of the TM5 is conformationally sensitive during the transport cycle. Our results indicate that the accessibility of some residues of TM5 take part in the transport pathway during the transport cycle.

Introduction

Glutamate is the major excitatory neurotransmitter in the central nervous system. The glutamate-neutral amino acid transporter family, also known as solute carrier family 1 (SLC1), includes many prokaryotic transporters as well as five excitatory amino acid transporters (EAAT) and two Na+-dependent neutral amino acid transporters. GLAST/EAAT1 [1,2] and GLT1/EAAT2 [3] were cloned from rat while EAAC1/EAAT3 [4] was cloned from rabbit. EAAT4 [5] and EAAT5 [6] were both cloned from human. EAATs are the key elements in the termination of the synaptic actions of glutamate by uptaking glutamate from the synaptic cleft into cytoplasm [1,2,7–9]. So they serve to keep the extracellular glutamate concentration below neurotoxic level.

Glutamate transporters have a non-conventional topology. The first six transmembrane segments, which are less conserved, form a distorted ‘amino-terminal cylinder’ and provide all inter-protein contacts, whereas the conserved transmembrane segments TM7 and TM8, together with hairpins HP1 and HP2,
form the binding pocket [23]. HP2 is the external gate of the transporter and HP1 is the internal one. They alternately open so that the substrate-binding site can be accessed from extracellular or intracellular solution respectively [23,32–35].

The trimeric interface of the glutamate transporter involving TMs 2, 4, and 5 is unchanged during transport [27]. To assess the functional significance of residues in TM5 of the cysteine-less version of EAAT1 (CL-EAAT1, in which the endogenous cysteines were replaced by serine or alanine, so that the interaction between the sulphydryl reagents and endogenous cysteines is abolished), cysteine mutants were introduced from position 291 to 300, the end half of the Cysteine-less EAAT1 (Fig. 1). We checked the activity and kinetic parameters of the mutants before and after treatments with the membrane-impermeable sulphydryl reagent MTSET ([2-trimethylammonium] methanethiosulfonate); furthermore we also analyzed the effect of the substrate and blocker on the inhibition of cysteine mutants by MTSET. Our results indicate that some residues of TM5 take part in the transport pathway during the transport cycle.

Results

Cysteine-scanning mutagenesis and impact of MTSET and MTSEA

Since the majority of TM5 is buried under the interior of the transporter, we only chose the end of the TM5, from position 291 to 300 to analyze the sensitivity of single cysteine mutants to MTSET. Cysteines were introduced one at a time into each of these positions of the Cysteine-less EAAT1. Cysteine-less EAAT1 has similar transport properties comparing with wild-type EAAT1, and it’s an excellent background in which to introduce single cysteine mutants to study the function of the residues [36]. After transient expression of the Cysteine-less EAAT1 and the cysteine mutants in HeLa cells, transport of D-[3H]aspartate was measured. The activity of the cysteine mutants at these positions ranged from 18.1 to 92.6% of the Cysteine-less EAAT1 (Fig. 2). We expressed each mutant in HeLa cells and then measured the accumulation of radiolabeled D-aspartate before and after exposure to the membrane-impermeable sulphydryl reagent MTSET. Transport by L296C, I297C, G299C single cysteine mutants was inhibited by 1.0 mM MTSET, while the activity of K300C got higher after exposure to MTSET (Fig. 3A). The sensitivity of L296C and G299C to MTSET was far greater than that of I297C, and the activity of these three mutants was inhibited by MTSET in a dose-dependent manner (Fig. 3B). An almost full inhibition of activity of L296C and G299C was observed when MTSET concentration was increased to 2.0 mM (Fig. 3B). With regard to the impact of the impermeant sulphydryl reagent MTSET on activity, the end half of the TM5 can be divided in two regions: 1) the internal region, including from position 291 to 295, where none of the cysteine mutants are sensitive to MTSET; and 2) the external region, from position 296 to 300, where the mutants are impacted by MTSET with the exception of A298C (Fig. 3A). This suggests that the introduced cysteines at the external region are exposed from the extracellular side. Furthermore we also checked the cysteine mutants of the internal region with the membrane-permeable sulphydryl reagent MTSEA [2-
aminoethyl methanethiosulfonate] to know whether it is exposed from the intracellular side. MTSEA had no inhibitory effect on the activity of the cysteine mutants of the internal region (Fig. 3C), so the internal region isn’t exposed from the intracellular side.

The biotinylation reagent only modifies proteins at the plasma membrane [37]. Surface biotinylation experiments showed that in the total samples of Cysteine-less EAAT1 and mutants, the major band has a mobility of 65–70 kDa, which represents mature monomeric forms of the transporter. The slower moving bands apparently represent dimeric/aggregate forms of the transporter (Fig. 4) [37,38]. In the case of the biotinylated samples of Cysteine-less EAAT1 and mutants, the major band with mobility of 65–70 kDa were observed (Fig. 4). L296C and G299C were present on the plasma membrane at similar levels of Cysteine-less EAAT1 (Fig. 4). Scanning of the bands from the biotinylated samples from three different experiments indicates that intensity of the 65–70 kDa bands of I297C and K300C is statistically different from that of Cysteine-less EAAT1 (one-way ANOVA with post-hoc multiple comparison test, \( p < 0.01 \)). The percentage values of Cysteine-less EAAT1 are 78.2 \( \pm \) 11.6, 23.7 \( \pm \) 6.4, 94.8 \( \pm \) 5.3 and 11.3 \( \pm \) 2.5 for L296C, I297C, G299C and K300C, respectively. This experiment indicated that the lack of activity of I297C and K300C was due to defective targeting of these mutant transporters to the plasma membrane (Fig. 4). There are no transporter bands in the lanes labeled SK, which illustrated the specificity of the antibody (Fig. 4).

The kinetic parameters of glutamate were examined. In the presence or absence of MTSET, there is no significance difference between the \( K_m \) values for L-glutamate of each mutant and that of Cysteine-less EAAT1 (Table 1). Furthermore the \( K_m \) values of Cysteine-less EAAT1 and mutants were similar in the presence and absence of MTSET (Table 1). In contrast, after exposure to MTSET L296C and G299C have a significantly lower \( V_{max} \) while K300C has a significantly higher one (Table 1).

**Effect of transporter ligands on impact of TM5 single mutants by MTSET**

For the cysteine mutants which are sensitive to MTSET, we checked the effects of transporter ligands on the sensitivity of single cysteine mutants to MTSET. From these experiments we tried to investigate the conformational change of TM5 in different stage of the transport cycle. The experiments were done in two stages. 1. Preincubation of HeLa cells expressing the single cysteine mutants with MTSET was done under various conditions reflecting different stages of the transporter (\( \pm Na, \pm substrate, \pm blocker \)). 2. After washing away the MTSET and substrate/blocker, the impact of the treatment was determined by measurement of transport.

**Figure 3. Effect of MTSET and MTSEA on uptake activity of single cysteine mutants of TM5.** HeLa cells expressing single cysteine mutants or Cysteine-less EAAT1, were preincubated in NaCl-containing medium with sulfhydryl reagent for 5 min at room temperature, washed twice with choline chloride-containing solution, and subsequently D-[\( ^3 \)H]-aspartate transport was assayed. Data represent percentage of the remaining uptake activity after incubation with sulfhydryl reagent relative to values obtained in the absence of sulfhydryl reagent. Values represent the mean \( \pm \) S.E. of at least three separate experiments each performed in triplicate. (A) Effect of MTSET on transport activity of single cysteine mutants of TM5. The concentration of MTSET used in this study was 1.0 mM. (B) Effect of different concentrations of MTSET on transport activity of L296C, I297C and G299C. (C) Effect of MTSEA on transport activity of single cysteine mutants of TM5. The concentration of MTSEA used in this study was 2.5 mM. doi:10.1371/journal.pone.0030961.g003
For L296C, I297C and G299C, we applied an appropriate concentration of MTSET respectively to keep the transport activity of mutants around 60% of the control so that we could investigate the effects of the transporter substrate and blocker on the sensitivity of single cysteine mutants to MTSET (Fig. 5A, B and C). For I297C, the substrate L-glutamate and the glutamate’s blocker TBOA had no effect on the inhibition of transport of I297C by MTSET, and we got the same result when NaCl was substituted by KCl (Fig. 5B). MTSET caused a stimulation of transport activity of K300C (201.2 ± 12.1% of control, n = 3) (Fig. 3A). TBOA is expected to “lock” EAAT1 in an outward-facing conformation, increases the proportion of protein trapped in an outward-facing conformation, thereby increasing the aqueous accessibility from the extracellular side. Indeed, the inhibition of L296C and G299C by MTSET was significantly increased in the presence of TBOA (Fig. 5A and C). 36.7 ± 2.3% and 40.6 ± 3.0% activity remained after treatment with MTSET in NaCl for the two mutants respectively (n = 3) (Fig. 5A and C). When the sodium-containing medium was either supplemented with glutamate or replaced by potassium, it would increase the proportion of inward-facing transporters. In the presence of L-glutamate, a small but significant potentiation of the inhibition by MTSET was observed with L296C (46.9 ± 4.1% of control in L-glutamate compared with 61.6 ± 3.2% of control in NaCl, n = 3) (Fig. 5A), and the same was true for potassium (49.2 ± 2.7% of control in KCl compared with 61.6 ± 3.2% of control in NaCl, n = 3) (Fig. 5A). The potentiation was not observed with c-aminobutyric acid (GABA), which are not substrates of EAAT1 (Fig. 5A), so it demonstrates the specificity of this effect by L-glutamate. On the other hand, L-glutamate did not have a significant effect on the inhibition of G299C by MTSET (Fig. 5C). The enhancement of K300C by MTSET in NaCl (255.4 ± 10.5% of control, n = 3) (Fig. 5D) was significantly decreased in the presence of L-glutamate, potassium and TBOA (187.2 ± 7.8%, 176.1 ± 5.1% and 131.3 ± 6.9% of control respectively, n = 3) (Fig. 5D). Our results indicate that the accessibility of some positions at the end of the TM5 is conformationally sensitive.

**Discussion**

The trimeric interface of the glutamate transporter involving TMs 2, 4, and 5 is rigid during transport [27]. The 3–4 loop of an
archaeal glutamate transporter homolog plays an important role during the transport cycle, and cleaving the 3–4 loop results in the inactivation of the transporter [39]. Previously we have analyzed the proximity and functional significance of residues in TM5 and TM8 of the cysteine-less version of GLT-1. TM5 is in close proximity to TM8 in the glutamate transporter, and the spatial relationship between these domains is altered during transport [40]. From these findings we presume that TM5 maybe also take part in the substrate transport.

The introduced cysteines can react, through their sulfhydryl group, with a variety of sulfhydryl reagents. These reagents react in an aqueous environment since the sulfhydryl-group of the cysteine residue must be in its ionized form (Cysteine-S\(^\text{2}\)). This reaction can lead to variable degrees of loss of function of the membrane protein, depending on the location of the cysteine and the importance of that position to the function of the protein. These sulfhydryl reagents react with the thiolate anion, and therefore, their reactivity appears to reflect accessibility of the introduced cysteine residues from the aqueous medium. These reagents include various MTS (methanethiosulfonate, CH\(_3\)-SO\(_2\)-S-R) reagents that differ in their size and charge. Some MTS reagents are membrane-permeable (MTSEA) and some are membrane-impermeable (MTSET). This difference in charge and bulk between the sulfhydryl reagents allows the investigation of specific positions changed into cysteine and allows the study of whether it is exposed from the extracellular or intracellular side.

When the amino acid residues 291–300 of the Cysteine-less EAAT1, located in the end of the TM5, all the mutants retain some level transport activity (Fig. 2). Three of ten of the mutants are inhibited by the membrane-impermeable sulfhydryl reagent MTSET (Fig. 3A). This suggests that these cysteines are exposed from the extracellular side. However, the end of the TM5 does not appear to form a completely open structure, because there are differences in sensitivity to MTSET between the different mutants (Fig. 3A). None of the cysteines introduced from position 291 to 295 are sensitive to MTSET, so these positions are not exposed from the external aqueous medium (Fig. 3A). MTSEA also had no inhibitory effect on the activity of these cysteine mutants (Fig. 3C). Therefore this region isn’t exposed from the intracellular side.

After exposure to MTSET the \(K_m\) values of the mutants have no change but \(V_{\text{max}}\) of L296C and G299C reduces, \(V_{\text{max}}\) of K300C increases (Table 1). This data suggest that the reaction of L296C, G299C and MTSET rescinds the transport activity while the reaction of K300C and MTSET increases the transport activity. The reaction of the introduced cysteines and MTSET doesn’t change the apparent affinity for glutamate, which means that the interaction of the mutants with L-glutamate isn’t impaired, even though HeLa cells expressing mutants were treated by MTSET.

TBOA increases the proportion of protein trapped in an outward-facing conformation, thereby increasing the aqueous accessibility from the extracellular side. Indeed, the inhibition of L296C and G299C by MTSET was significantly increased in the

---

**Figure 5. Effect of the composition of the external medium on the inhibition of single cysteine mutants by MTSET.** HeLa cells expressing the single cysteine mutants L296C (A), 1297C (B), G299C (C) or K300C (D), were preincubated for 5 min in the presence or absence of 0.2 (A), 1.0 (B), 0.6 (C) or 0.01 (D) mM MTSET. The indicated preincubation solutions contained NaCl, NaCl+1mM L-glutamate, NaCl+20 \(\mu\)M TBOA, NaCl+1mM GABA, KCl, choline chloride. Subsequently the cells were washed and \(D^{[3]H}\)-aspartate transport was measured as described under “Materials and methods”. Values are given as a percentage of control (preincubation without MTSET) and represent the mean ± S.E. of at least three different experiments done in triplicate.

doi:10.1371/journal.pone.0030961.g005
presence of TBOA (Fig. 5A and C). There are three possibilities for this potentiation. One of the possibilities is that TBOA increases the aqueous accessibility of these positions from the extracellular aqueous medium. The other one is that after TBOA binding to the pocket, the external gate opens to the extracellular side which exposes the transport pathway to the extracellular solution [32,41], so these positions might be expose to the transport pathway. Or a combination of these first two possibilities may be occurring. When the sodium-containing medium was either supplemented with glutamate or replaced by potassium, it would promote the formation of the inward-facing conformation with the external gate closed. In the presence of L-glutamate, a small but significant potentiation of the inhibition by MTSET was observed with L296C (Fig. 5A). On the other hand, L-glutamate did not have a significant effect on the inhibition of G299C by MTSET (Fig. 5C). These results suggest that G299C indeed is both exposed to the extracellular aqueous medium and the transport pathway in the presence of TBOA which keeps the external gate opening, so Gly-299 contact with the transport pathway. In this situation the extent of the exposure of G299C is maximal. In the presence of L-glutamate which keep the external gate closed G299C can't communicate the extracellular medium via the transport pathway, only directly exposes to the extracellular side, so the accessibility was decreased under conditions favoring the inward facing conformation of the transporter comparing with that in the outward facing conformation. In our earlier studies about the cysteine mutant G297C of GLT-1 (GLT-1 residue Gly-297 corresponds to Gly-299 of EAAT1) we also got the same results for the accessibility under different conditions [40]. As for L296C, L-glutamate and TBOA both cause a potentiation of the inhibition of transport by MTSET, but TBOA cause a potentiation to a higher extent (Fig. 5A). L296C might also be both exposed to the extracellular aqueous medium and the transport pathway in the presence of TBOA. In the presence of L-glutamate L296C can't communicate with the extracellular medium via the transport pathway, is only directly exposed to the extracellular side, so the accessibility was decreased compared with that in the presence of TBOA. However the transport of the substrate causes L296C to be much more directly exposed to the extracellular side, so the accessibility was decreased under conditions favoring the inward facing conformation of the transporter with that in the outward facing conformation. The conformational change may include the compensatory shifting of other parts of the transporter. Now it is not clear what the nature of this conformational change is. The reactivity at this position was conformationally sensitive (Fig. 5D). The enhancement of K300C by MTSET was significantly decreased in the presence of L-glutamate and TBOA (Fig. 5D).

All these facts suggest that the accessibility of some positions of the external part of the TM5 is conformationally sensitive during the transport cycle. Our results indicate that some residues of TM5 take part in the transport pathway during the transport cycle.

Materials and Methods

Materials

D-[3H]-aspartate (11.3 Ci/mmol) and L-[3H]-glutamate (49.9 Ci/mmol) were purchased from PerkinElmer Inc. DL-TBOA was purchased from Tocris Bioscience. L-glutamate was purchased from Sigma. MTSET was purchased from Biotium Inc. DOTAP was purchased from Roche Molecular Biochemicals. DMEM, FCS, Trypsin(0.25%)-EDTA were purchased from Thermo Fisher Scientific Inc. Restriction enzymes were purchased from New England Biolabs. T4 Polynucleotide Kinase, T4 DNA Kinase, T4 DNA Polymerase, and T4 DNA Ligase were purchased from Roche. All other reagents were analytical grade.

Generation and Subcloning of Mutants

The Cysteine-less EAAT1 in the vector pBluescript SK(−) (Stratagene) will be used as a parent for site-directed mutagenesis. The parent DNA was used to transform Escherichia coli strain JM109 (dut–, ung–). From one of the transformants, single-stranded uracil-containing DNA was isolated upon growth in uridine-containing medium according to the standard protocol from Stratagene using helper phage R408. This yields the sense strand, and consequently mutagenic primers were designed to be antisense. Restriction enzymes BstEII and BstII were used to subclone the mutations into the construct containing Cysteine-less EAAT1 in the vector pBluescript SK(−). The subcloned DNA fragments were sequenced on both strands between the two restriction sites noted.

Cell Growth and Expression

HeLa cancer cell line was purchased from ATCC (Manassas, VA). HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS), 200 units/ml penicillin, 200 μg/ml streptomycin, and 2 mM glutamine. Heterologous expression of the wild type and mutant transporters was done as follows: HeLa cells plated on 24-well plates were infected with recombinant vaccinia/T7 virus vTF [42], and transfected with plasmid DNA encoding Cysteine-less EAAT1, mutants, or the vector pBluescript SK− alone using the transfection reagent DOTAP, as described [43]. Cells were incubated at 37°C for 16-20 hours.

Cell Surface Biotinylation

After expression of transporters in HeLa cells (in 12-well plates), the medium was aspirated and the cells were washed twice with 2 ml/well of phosphate-buffered saline (PBS) containing 0.1 mM CaCl2 and 1 mM MgCl2 (PBS/CM). The cells were incubated on ice in 500 μl of 1.5 mg/ml NHS-SS-biotin (Pierce, Inc., Rockford, IL) in 20 mM HEPEs, pH 9.0, 2 mM CaCl2, and 150 mM NaCl for two successive 20-min incubations. After labeling, the cells in each well were rinsed briefly with 1 ml of 100 mM glycine in PBS/CM and incubated in the same solution for 20 min on ice to quench unreacted NHS-SS-biotin. The cells were dissolved in 100 μl of lysis buffer consisting of 1% Triton X-100, 1% SDS, 150 mM NaCl, 5 mM EDTA, and 50 mM Tris-HCl (pH 7.5) by gentle shaking on ice for approximately 1 h until the cells were completely lysed, as assessed by light microscopy. The lysates from each well were then diluted by the addition of 900 μl of lysis buffer to reduce the concentration of SDS and clarified by centrifugation for 10 min at 16000g at 4°C. The biotinylated proteins were recovered from the supernatant solution by adding 100 μl of streptavidin-agarose beads (Pierce, Inc., Rockford, IL) and incubating 1 hour at 4°C with gentle agitation. The beads were washed three times with 1 ml of lysis buffer, twice with high-salt lysis buffer (lysis buffer containing 500 mM NaCl and only 0.1% Triton X-100), and once with 50 mM Tris-HCl (pH 7.5). The biotinylated proteins were finally eluted from the beads in 100 μl of SDS buffer according to the manufacturer’s recommendation at 60°C for 10 min, 3 min on ice and then were centrifuged. Total samples were obtained by washing cells expressing Cysteine-less
EAAT1 or mutants in 24-well plates twice with 1 ml/well of phosphate-buffered saline/CM, followed by lysis in SDS sample buffer, heating for 3 min at 60°C, and centrifugation. Samples were separated by SDS-polyacrylamide gel electrophoresis (10% gel) and transferred to nitrocellulose. The EAAT1 protein was detected with the antibody to EAAT1. Scanning and quantification of bands on the developed films was done using a Fluor-S™ MultiImager scanner with MultiAnalyst software, both from Bio-Rad.

Transport
Transport of radioactive D-[3H]-aspartate or L-[3H]-glutamate was measured 16–20 hours post transfection. Plates were taken out. Wells were washed once with 1 ml of the choline solution (150 mM choline chloride, 5 mM KPi, pH 7.4, 0.5 mM MgSO₄, and 0.3 mM CaCl₂). Each well was then incubated for 10 min at room temperature with 200 μl of radioactive sodium uptake solution (150 mM NaCl, 5 mM KPi, pH 7.4, 0.5 mM MgSO₄, and 0.3 mM CaCl₂) which supplemented with 0.4 μg of the tritium-labeled substrate. Uptake was stopped after 10 min by removing the transport solution and washing the cells twice in cold sodium uptake solution. HeLa cells were lysed with SDS, and followed by scintillation counting.

Inhibition Studies with Sulphydryl Reagent
Before the transport measurements, the cells adhering to 24-well plates were washed with the choline solution. Each well was then incubated at room temperature with 200 μl of the preincubation medium containing MTSET or MTSEA (the different compositions are indicated in the figure legends). After 5 min, the medium was aspirated, and the cells were washed twice with 1 ml of the choline solution. Subsequently, each well was then incubated for 10 min at room temperature with 200 μl of radioactive sodium uptake solution. Then HeLa cells were lysed with SDS, and followed by scintillation counting. Each experiment was performed at least three times. The concentration of MTSET chosen in the different experiments was optimized according to the mutants used.

Kinetics
HeLa cells expressing Cysteine-less EAAT1 or mutants were measured for the ability to accumulate L-glutamate (200 μM; 100 nM L-[3H]-glutamate, 199.9 μM unlabeled L-glutamate) as a function of time. Uptake kept linear for 10 min. HeLa cells were preincubated for 5 min in the presence or absence of 1.0 mM MTSET. Subsequently the cells were washed and incubated with 100 nM L-[3H]-glutamate in final unlabeled L-glutamate concentrations of 1, 5, 10, 50, 100, 250, 500 and 1000 μM for 10 min at room temperature. Then L-[3H]-glutamate transport was measured. Affinity constant (K_a) and maximum velocity (V_max) were determined by the Michaelis-Menten equation using KaleidaGraph (Synergy Software, Reading, PA). V_max is expressed as a percent of that of untreated Cysteine-less EAAT1.

Author Contributions
Conceived and designed the experiments: SQ. Performed the data analysis: XZ SQ. Wrote the paper: SQ.

References
1. Storck T, Schulte S, Hofmann K, Stoffel W (1992) Structure, expression, and functional analysis of a Na⁺-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci U S A 89: 10955–10959.
2. Tanaka K (1993) Expression cloning of a rat glutamate transporter. Neurosci Res 16: 149–153.
3. Pines G, Danbolt NC, Bjoras M, Zhang Y, Bendahan A, et al. (1992) Cloning and expression of a rat brain L-glutamate transporter. Nature 360: 464–467.
4. Kanai Y, Hediger MA (1992) Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 360: 467–471.
5. Arriza JL, Eliaosof S, Kavanagh MP, Amara SG (1995) An excitatory amino-acid transporter with properties of a ligand-gated chloride channel. Nature 375: 599–603.
6. Arriza JL, Eliaosof S, Kavanagh MP, Amara SG (1997) Excitatory amino acid transporter 5, a ratial glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci U S A 94: 4155–4160.
7. Kanner BI, Sharon I (1978) Active transport of L-glutamate by membrane vesicles isolated from rat brain. Biochemistry 17: 3949–3953.
8. Zerangue N, Kavanagh MP (1996) Flux coupling in a neuronal glutamate transporter. J Biol Chem 271: 14282–14287.
9. Levy LM, Warr O, Attwell D (1998) Stoichiometry of the glial glutamate transporter GLT-1 from rat brain. Proc Natl Acad Sci U S A 95: 1710–1715.
10. Rosental N, Bendahan A, Kanner BI (2006) Multiple consequences of mutating two conserved beta-bridge forming residues in the translocation cycle of a neuronal glutamate transporter. J Biol Chem 281: 27905–27915.
11. Tao Z, Grewer C (2007) Cooperation of the conserved aspartate 439 and bound amino acid substrate is important for high-affinity Na⁺/glutamate co-transport in rat brain. J Neurosci 27: 19231–19237.
12. Teichman S, Kanner BI (2007) Aspartate-444 is essential for productive substrate interactions in a neuronal glutamate transporter. J Gen Physiol 129: 527–539.
13. Grewer C, Balani P, Weidenfeller C, Bartusel T, Tao Z, et al. (2005) Individual accessibility of the TM5 of EAAT1. Proc Natl Acad Sci U S A 102: 10263–10268.
30. Leary GP, Stone EF, Holley DC, Kavanaugh MP (2007) The glutamate and chloride permeation pathways are colocalized in individual neuronal glutamate transporter subunits. J Neurosci 27: 2938–2942.

31. Koch HP, Brown RL, Larsson HP (2007) The glutamate-activated anion conductance in excitatory amino acid transporters is gated independently by the individual subunits. J Neurosci 27: 2943–2947.

32. Boudler O, Ryan RM, Yermool D, Shimamoto K, Gouaux E. (2007) Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter. Nature 445: 387–393.

33. Huang Z, Tajibhorbid E. (2008) Dynamics of the extracellular gate and ion-substrate coupling in the glutamate transporter. Biophys J 95: 2292–2300.

34. Shrivastava IH, Jiang J, Amara SG, Bahar I (2008) Time-resolved mechanism of extracellular gate opening and substrate binding in a glutamate transporter. J Biol Chem 283: 20690–20699.

35. Crisman T, Qu S, Kanner BI, Forrest L (2009) Inward-facing conformation of glutamate transporters as revealed by their inverted-topology structural repeats. Proc Natl Acad Sci U S A 106: 20752–20757.

36. Seal RP, Amara SG (1996) A reentrant loop domain in the glutamate carrier EAAT1 participates in substrate binding and translocation. Neuron 21: 1487–1498.

37. Bennett ER, Su H, Kanner BI (2000) Mutation of arginine 44 of GAT-1, a (Na+ + Cl-)-coupled γ-aminobutyric acid transporter from rat brain, impairs net flux but not exchange. J Biol Chem 275: 34106–34113.

38. Bennett ER, Kanner BI (1997) The membrane topology of GAT-1, a (Na+ + Cl-)-coupled γ-aminobutyric acid transporter from rat brain. J Biol Chem 272: 1203–1210.

39. Compton EL, Taylor EM, Mindell JA (2010) The 3-4 loop of an archaean glutamate transporter homolog experiences ligand-induced structural changes and is essential for transport. Proc Natl Acad Sci U S A 107: 12940–12945.

40. Zhang X, Qu S (2011) Proximity of Transmembrane Segments 5 and 8 of the Glutamate Transporter GLT-1 Inferred from Paired Cysteine Mutagenesis. PLoS ONE 6: e21208.

41. Qu S, Kanner BI (2008) Substrates and non-transportable analogues induce structural rearrangements at the extracellular entrance of the glial glutamate transporter GLT-1. J Biol Chem 283: 26391–26400.

42. Fuerst TR, Niles EG, Studier FW, Moss B (1986) Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A 83: 8122–8126.

43. Keynan S, Suh YJ, Kanner BI, Rudnick G (1992) Expression of a cloned γ-aminobutyric acid transporter in mammalian cells. Biochemistry 31: 1974–1979.